---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-043801"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:56:42.864986+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Anteris Technologies not renewing supply agreement with 4C Medical for ADAPT tissue

## Summary
- On Nov 26, 2025, Anteris notified 4C Medical of non-renewal of Second Amended Supply and License Agreement.
- Agreement supplied ADAPT tissue for 4C's transcatheter mitral/tricuspid valve devices; term would expire June 1, 2026.
- No early termination penalties incurred; company states termination does not materially impact financial results.

## SEC filing metadata
- accession: 0001140361-25-043801
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036125043801/0001140361-25-043801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036125043801/ef20060235_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-043801
- JSON: https://secwatch.observer/filing/0001140361-25-043801.json
- Plain text: https://secwatch.observer/filing/0001140361-25-043801.txt

## Key facts
- Material Agreements
  Anteris Technologies Global Corp. terminated Second Amended and Restated Supply and License Agreement, as amended with 4C Medical Technologies, Inc. (effective 2025-11-26).
  - Action: termination
  - Agreement: supply
  - Counterparty: 4C Medical Technologies, Inc.
  - Effective: 2025-11-26
  source text: On November 26, 2025, Anteris Technologies Global Corp. (the “Company”) notified 4C Medical Technologies, Inc. (“4C”) that it was not renewing the Second Amended and Restated Supply and License Agreement, as amended (the “Supply Agreement”), between the Company and 4C, which provided for the supply by the Company to 4C of ADAPT ® tissue used in 4C’s production of medical devices related to transcatheter mitral valve and tricuspid valve regurgitation therapy and granted a limited license to the Company’s related sterilization methods in connection with use of ADAPT ® tissue by 4C in its production of medical devices.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2011514/000114036125043801/0001140361-25-043801-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.